(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5.69% € 3.16
Live Chart Being Loaded With Signals
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases...
Stats | |
---|---|
Volumen de hoy | 37 188.00 |
Volumen promedio | 66 924.00 |
Capitalización de mercado | 165.49M |
EPS | €0 ( 2024-03-28 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.300 |
ATR14 | €0.0110 (0.35%) |
Volumen Correlación
Inventiva SA Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Inventiva SA Correlación - Moneda/Commodity
Inventiva SA Finanzas
Annual | 2023 |
Ingresos: | €17.48M |
Beneficio Bruto: | €17.50M (100.13 %) |
EPS: | €-2.43 |
FY | 2023 |
Ingresos: | €17.48M |
Beneficio Bruto: | €17.50M (100.13 %) |
EPS: | €-2.43 |
FY | 2022 |
Ingresos: | €12.18M |
Beneficio Bruto: | €11.18M (91.83 %) |
EPS: | €-1.310 |
FY | 2021 |
Ingresos: | €4.19M |
Beneficio Bruto: | €0.00 (0.00 %) |
EPS: | €-1.465 |
Financial Reports:
No articles found.
Inventiva SA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico